GSK-3β mediates ischemia-reperfusion injury by regulating autophagy in DCD liver allografts.

Tingting Liu(Liaoning University), Yongfeng Liu(Liaoning University), Ying Cheng(Jilin Province Tumor Hospital), Qi Pan(Guangzhou HKUST Fok Ying Tung Research Institute), Jianan Yu(China University of Geosciences (Beijing)), Yang Han(Shandong University), Wenshi Liu(Liaoning University), Wu Lv(Liaoning Cancer Hospital & Institute)
PubMed
January 1, 2019
Cited by 4

Related Papers

SOAPdenovo2: an empirically improved memory-efficient short-read <i>de novo</i> assembler
|GigaScience|2012|5.6k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504